Merck and Roche have agreed to renew their current distribution agreement for the Biochemical Reagents and Kapa Biosystems product portfolios, as well as select real-time quantitative PCR & Nucleic Acid Purification products.
Basel/Switzerland — Under the agreement, Merck will continue to employ its sales, marketing and e-commerce expertise, providing customers with continued access to Roche products.
This agreement, initiated between the two life science industry leaders in 2015 and originally extending to 2020, will now continue for an additional five years, maintaining global exclusivity in most regions. The global distribution agreement will extend through 2025 and is effective January 1, 2019.
Roche signed the global exclusive distribution agreement for its biochemical reagent portfolio with Sigma-Aldrich in July 2015. Following Merck's acquisition of Sigma-Aldrich in the same year, this agreement became part of Merck and a growth driver for the life science business, enabling the company to offer high-quality brand-name tools for genomics, proteomics and cell analysis.